Compare NRK & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRK | VIR |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 878.5M | 773.5M |
| IPO Year | N/A | 2019 |
| Metric | NRK | VIR |
|---|---|---|
| Price | $9.98 | $6.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.73 |
| AVG Volume (30 Days) | 187.3K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.95 | $4.16 |
| 52 Week High | $11.09 | $14.45 |
| Indicator | NRK | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 32.16 | 61.34 |
| Support Level | $10.03 | $6.49 |
| Resistance Level | $10.15 | $6.89 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 5.37 | 82.30 |
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.